A significant number of biologic drugs are expected to lose patent protection by 2030, creating a substantial opportunity for biosimilar manufacturers.
INTERVIEW
the biosimilars space while focusing on both domestic and international markets. A significant number of biologic drugs are expected to lose patent protection by 2030, creating a substantial opportunity for biosimilar manufacturers. The adoption of biosimilars is increasing due to their potential to transform expensive treatments into more accessible and affordable ones. There is a growing investment in biosimilar research and development, driven by both private and government initiatives. Rising prevalence of chronic diseases and increased healthcare awareness are boosting demand for affordable biosimilar treatments.
By adhering to international regulatory standards, Indian companies can streamline their entry and enhance market share in regulated markets. India ' s cost-effective manufacturing capabilities provide a competitive edge. By leveraging this, companies can offer high-quality biosimilars at lower prices, making them attractive in both
domestic and international markets. Collaborations with global pharmaceutical companies can help Indian firms gain access to advanced technologies and markets, enhancing their global footprint
Which factors have shaped Lupin ' s biosimilars portfolio and global strategy?
A significant number of biologic drugs are expected to lose patent protection by 2030, creating a substantial opportunity for biosimilar manufacturers.
Lupin ' s biosimilars portfolio and global strategy are driven by a combination of factors which enable Lupin to capitalize on emerging opportunities and enhance its global presence in the biosimilars industry. The company has made substantial investments in research and development, and established multiple research centers, including Lupin Research Park, and Lupin Bioresearch Center. Lupin has developed end-to-end capabilities:“ Vial-to-Vial” for biosimilar development.
Lupin has had a strong track record of successful scale-ups and cost-effective, high yielding manufacturing processes. It has invested in building world-class manufacturing capabilities and
26
BioVoiceNews | April 2025